Vaxess Technologies

Vaxess Technologies is transforming home delivery of next generation therapies. Vaxess's platform combines a proprietary microarray patch and applicator, capable of delivering a wide range of therapies. Advanced biomaterials used for the dissolvable microarray tips enable the greatest levels of dose delivery control, and can be modified to deliver different payloads. Additionally, the patch does not require refrigeration, enabling delivery to low resource settings. Vaxess has raised more than $100 million in grant and venture capital funding from groups such as RA Capital Management, Engine Ventures, GHIC, Mission BioCapital, BARDA, DARPA, NIH, NSF and the Gates Foundation. The company has also generated strong clinical and in-vivo proof of concept in the platform with a wide range of molecules. For more information, please visit the company website at or send additional inquiries to contact@vaxess.com.Find more information at